Prostate cancer
Hormonal suppression therapy in advanced prostate cancer. GnRH analogs (triptorelin, leuprolide) act via down-regulation of pituitary LH/FSH secretion.
Peptides on this topic
6 peptidi con ricerche su questo argomentoBuserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US.
- RCT sull'uomoSuppresses sex hormones after an initial flare — the basis of efficacy in endometriosis and prostate cancer.
- Studio sull'uomoAlso available as a nasal spray — like nafarelin, one of the few nasally administered GnRH agonists.
Degarelix (trade name Firmagon) is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike GnRH agonists, it blocks the receptor directly and does not trigger an initial testosterone surge (flare). It is an approved prescription medicine for the treatment of advanced, hormone-dependent prostate cancer. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation.
- RCT sull'uomoIn a randomized phase III study, degarelix lowered testosterone without the initial surge (flare) seen with GnRH agonists and achieved castrate-range suppression over the study year, comparable to leuprorelin.
- RCT sull'uomoIn the phase III study, degarelix produced a faster initial decline in testosterone and prostate-specific antigen (PSA) than the agonist comparator arm.
Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others.
- Studio sull'uomoHuman studies observed suppression of circulating sex hormones down to castration levels.
- RCT sull'uomoIn a randomized trial, premenopausal patients receiving concurrent chemotherapy showed a lower rate of ovarian failure when goserelin was added.
Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas).
- RCT sull'uomoSuppresses sex hormones via a yearly implant — in precocious puberty and prostate cancer.
- Studio sull'uomoImplant form (once a year) instead of regular injections.
Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation.
- RCT sull'uomoWith continuous exposure, LH and FSH are suppressed, with subsequent lowering of sex steroids.
- RCT sull'uomoIn randomized endometriosis studies, leuprorelin was associated with greater reduction of pain parameters versus placebo.
Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty.
- RCT sull'uomoSuppression of testosterone into the castration range (<50 ng/dL) within 4 weeks in men with prostate cancer documented
- RCT sull'uomoReduction of endometriosis pain and lesion size demonstrated versus placebo in randomised trials